A key role of GARP in the immune suppressive tumor microenvironment

Oncotarget

Volumn 7, Issue 28, 2016, Pages 42996-43009

  Hahn, Susanne A ^a   Neuhoff, Annemarie ^a   Landsberg, Jenny ^c   Schupp, Jonathan ^a   Eberts, Daniela ^a   Leukel, Petra ^a   Bros, Matthias ^a   Weilbaecher, Martin ^a   Schuppan, Detlef ^a,b   Grabbe, Stephan ^a   Tueting, Thomas ^c   Lennerz, Volker ^a   Sommer, Clemens ^a   Jonuleit, Helmut ^a   Tuettenberg, Andrea ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

GARP; Melanoma; Tolerance; Treg; Tumor microenvironment

Indexed keywords

5' NUCLEOTIDASE; ALPHA INTERFERON; CD39 ANTIGEN; GLYCOPROTEIN A REPETITION PREDOMINANT; LYMPHOCYTE SURFACE MARKER; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOKINE; GAMMA INTERFERON; LRRC32 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MELANOCYTE; MELANOMA CELL LINE; MEMBRANE BINDING; PHENOTYPE; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SURFACE PROPERTY; TUMOR MICROENVIRONMENT; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; TUMOR CELL LINE;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; MACROPHAGES; MELANOMA; MEMBRANE PROTEINS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84978655731     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9598     Document Type: Article

References (47)

1. Bhatia S, Tykodi SS and Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park, NY). 2009; 23(6):488-496
2. Gajewski TF, Meng Y and Harlin H. Immune suppression in the tumor microenvironment. Journal of immunotherapy (Hagerstown, Md: 1997). 2006; 29(3):233-240
3. Ahmad F, Mani J, Kumar P, Haridas S, Upadhyay P and Bhaskar S. Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice. PloS one. 2011; 6(9):e25424
4. Tucci M, Stucci S, Passarelli A, Giudice G, Dammacco F and Silvestris F. The immune escape in melanoma: role of the impaired dendritic cell function. Expert review of clinical immunology. 2014; 10(10):1395-1404
5. Umansky V and Sevko A. Melanoma-induced immunosuppression and its neutralization. Seminars in cancer biology. 2012; 22(4):319-326
6. Aliagas E, Vidal A, Texido L, Ponce J, Condom E and Martin-Satue M. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators of inflammation. 2014; 2014:509027
7. Ruiz-Arguelles GJ and San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clinic proceedings. 1994; 69(7):684-690
8. Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P, Feoktistov I, Moses HL and Novitskiy SV. Role of TGF-beta signaling in generation of CD39+CD73+ myeloid cells in tumors. Journal of immunology (Baltimore, Md: 1950). 2014; 193(6):3155-3164
9. Hahn SA, Stahl HF, Becker C, Correll A, Schneider FJ, Tuettenberg A and Jonuleit H. Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4(+) T cells. Blood. 2013; 122(7):1182-1191
10. Gai XD, Song Y, Li C, Lei YM and Yang B. Potential role of plasmacytoid dendritic cells for FOXP3+ regulatory T cell development in human colorectal cancer and tumor draining lymph node. Pathology, research and practice. 2013; 209(12):774-778
11. Wartenberg M, Zlobec I, Perren A, Koelzer VH, Gloor B, Lugli A and Karamitopoulou E. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transitiontype tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. Oncotarget. 2015; 6:4190-201. doi: 10.18632/oncotarget.2775
12. Huang X, Zou Y, Lian L, Wu X, He X, He X, Wu X, Huang Y and Lan P. Changes of T cells and cytokines TGFbeta1 and IL-10 in mice during liver metastasis of colon carcinoma: implications for liver anti-tumor immunity. Journal of gastrointestinal surgery. 2013; 17(7):1283-1291
13. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. Journal of immunology research. 2014; 2014:149185
14. Jonuleit H and Schmitt E. Regulatory T-cells in antitumor therapy: isolation and functional testing of CD4+CD25+ regulatory T-cells. Methods in molecular medicine. 2005; 109:285-296
15. Shen E, Zhao K, Wu C and Yang B. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cellcell contact partially via TGF-beta production. Cell biology international. 2011; 35(7):705-712
16. Kim MH, Koo JS and Lee S. FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph nodepositive breast cancer patients. Oncology. 2013; 85(2):128-136
17. Ott PA, Hodi FS and Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clinical cancer research. 2013; 19(19):5300-5309
18. Schlosser HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL and von Bergwelt-Baildon M. Overcoming tumor-mediated immunosuppression. Immunotherapy. 2014; 6(9):973-988
19. Clark P. Protease-mediated ectodomain shedding. Thorax. 2014; 69(7):682-684
20. Weber S and Saftig P. Ectodomain shedding and ADAMs in development. Development (Cambridge, England). 2012; 139(20):3693-3709
21. Kim C, Cho Y, Kang CH, Kim MG, Lee H, Cho EG and Park D. Filamin is essential for shedding of the transmembrane serine protease, epithin. EMBO reports. 2005; 6(11):1045-1051
22. Peng J, Tsang JY, Ho DH, Zhang R, Xiao H, Li D, Zhu J, Wang F, Bian Z, Lui VC, Xu A, Tam PK, Lamb JR, Xia H and Chen Y. Modulatory effects of adiponectin on the polarization of tumor-associated macrophages. International journal of cancer. 2015;137(4):848-58. doi: 10.1002/ijc.29485
23. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S and Tortora G. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer treatment reviews. 2015; 41(2):114-121
24. Shin SJ, Jeon YK, Cho YM, Lee JL, Chung DH, Park JY and Go H. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. The oncologist. 2015; 20(11):1253-1260
25. Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK and Chung DH. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. European journal of cancer (Oxford, England: 1990). 2015; 51(17):2698-2707
26. Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K and Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Frontiers in immunology. 2013; 4:82
27. Kadison AS and Morton DL. Immunotherapy of malignant melanoma. The Surgical clinics of North America. 2003; 83(2):343-370
28. Konjevic G, Jovic V, Radulovic S, Jelic S, Dzodic R and Spuzic I. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha. Neoplasma. 2001; 48(3):175-181
29. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of highdose interferon-alpha 2b treatment. Journal of translational medicine. 2010; 8:76
30. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA and Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer treatment reviews. 2014; 40(9):1056-1064
31. Pico de Coana Y, Choudhury A and Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in molecular medicine. 2015; 21(8):482-91. doi: 10.1016/j.molmed.2015.05.005
32. Wang R, Wan Q, Kozhaya L, Fujii H and Unutmaz D. Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PloS one. 2008; 3(7):e2705
33. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, Kelley PM, Pebusque MJ, Theillet C, Birnbaum D and Gaudray P. Detailed map of a region commonly amplified at 11q13->q14 in human breast carcinoma. Cytogenetics and cell genetics. 1997; 79(1-2):125-131
34. Edwards J, Krishna NS, Witton CJ and Bartlett JM. Gene amplifications associated with the development of hormoneresistant prostate cancer. Clinical cancer research. 2003; 9(14):5271-5281
35. Li MO, Wan YY, Sanjabi S, Robertson AK and Flavell RA. Transforming growth factor-beta regulation of immune responses. Annual review of immunology. 2006; 24:99-146
36. Thomas DA and Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell. 2005; 8(5):369-380
37. Tuettenberg A, Schmitt E, Knop J and Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. Journal der Deutschen Dermatologischen Gesellschaft. 2007; 5(3):190-196
38. Correll A, Tuettenberg A, Becker C and Jonuleit H. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Experimental dermatology. 2010; 19(8):e213-221
39. Becker M, Muller CB, De Bastiani MA and Klamt F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histology and histopathology. 2014; 29(1):21-31
40. Tang X, Mo C, Wang Y, Wei D and Xiao H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology. 2013; 138(2):93-104
41. Murray PJ and Wynn TA. Obstacles and opportunities for understanding macrophage polarization. Journal of leukocyte biology. 2011; 89(4):557-563
42. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D and Paschen A. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer research. 2012; 72(2):460-471
43. Wang Z, Seliger B, Mike N, Momburg F, Knuth A and Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer research. 1998; 58(10):2149-2157
44. Jonuleit H, Schmitt E, Schuler G, Knop J and Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. The Journal of experimental medicine. 2000; 192(9):1213-1222
45. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J and Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. The Journal of experimental medicine. 2001; 193(11):1285-1294
46. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T and Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. Journal of immunological methods. 2002; 259(1-2):95-110
47. Jonuleit H, Knop J and Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Archives of dermatological research. 1996; 289(1):1-8